| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $143.4M | +89.2% |
| SG&A Expense | $44.0M | +110.2% |
| Operating Income | -$187.4M | -93.7% |
| Interest Expense | $0 | -100.0% |
| Net Income | -$167.5M | -70.7% |
| EPS (Basic) | -$3.72 | +77.5% |
| EPS (Diluted) | -$3.72 | +77.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $64.4M | -84.1% |
| Short-term Investments | $275.3M | — |
| Current Assets | $345.0M | -15.7% |
| Total Assets | $414.1M | -8.6% |
| Current Liabilities | $25.0M | +18.3% |
| Total Liabilities | $53.8M | +13.0% |
| Stockholders' Equity | $360.2M | -11.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$139.7M | -72.2% |
| Capital Expenditures | $4.4M | -46.3% |
| Investing Cash Flow | -$305.1M | -3292.8% |
| Financing Cash Flow | $103.5M | -79.1% |
| Free Cash Flow | -$144.2M | -61.2% |